Showing results (71-80 of 103) with videos related to

Sort By:
Pageof 11
The Journal of Experimental Medicine|August 16, 2023
IL-6 translation is a therapeutic target of human cytokine release syndromeYuzhuo Yang, Yajing Zhang, Xiaoyan Xing, et al.
Cell Reports|November 15, 2023
p53-responsive CMBL reprograms glucose metabolism and suppresses cancer development by destabilizing phosphofructokinase PFKPYingdan Huang, Chen Xiong, Chunmeng Wang, et al.
Leukemia|July 17, 2021
Long-term activity of tandem CD19/CD20 CAR therapy in refractory/relapsed B-cell lymphoma: a single-arm, phase 1-2 trialYajing Zhang, Yao Wang, Yang Liu, et al.
American Journal of Hematology|March 10, 2026
Five-Year Follow-Up: Tandem CD19/CD20 CAR T Therapy Enduring Impact on Refractory/Relapsed Non-Hodgkin LymphomaFuxin Han, Yadi Zhong, Chuan Tong, et al.
Biorxiv : the Preprint Server for Biology|May 13, 2026
CsFDL1-CsFTL3 complex represses CsFTL3 via negative feedback to fine-tune flowering in Chrysanthemum seticuspeShuang Wang, Chunmeng Wang, Zishu Mei, et al.
Science Advances|May 8, 2026
Antigen spreading mediates heterogeneous solid tumor eradication by DNA demethylating agent-programmed CAR T cellsYelei Guo, Chuan Tong, Jianshu Wei, et al.
Plant, Cell & Environment|June 3, 2026
CsFDL1-CsFTL3 Complex Represses CsFTL3 via Negative Feedback to Fine-Tune Flowering in Chrysanthemum seticuspeShuang Wang, Chunmeng Wang, Zishu Mei, et al.
Cancer Research and Treatment|March 14, 2023
Clinicopathological Analysis and Treatment of Adult Patients with Inflammatory Myofibroblastic Tumor: A 15-Year Single- Center StudyXin Liu, Chengcheng Gong, Jieyun Zhang, et al.
Blood|August 2, 2024
Epigenetic agents plus anti-PD-1 reprogram the tumor microenvironment and restore antitumor efficacy in Hodgkin lymphomaJing Nie, Chunmeng Wang, Liangtao Zheng, et al.
Molecular Cancer|May 15, 2023
Epigenetic reprogramming of Runx3 reinforces CD8 + T-cell function and improves the clinical response to immunotherapyZongzhi Liu, Xiang Li, Yibo Gao, et al.
Pageof 11